Eli Lilly Receives FDA Breakthrough Therapy Designation for Alzheimer's Treatment
Source: Streetwise Reports  (6/24/21)
Eli Lilly and Co's shares traded 8% higher and reached a new 52-week high after the company reported the FDA granted its investigational antibody therapy donanemab Breakthrough Therapy designation for use in treating Alzheimer's disease. More >

Price Target Raised on Biopharma Achieving Positive Atopic Dermatitis Study Results
Source: Streetwise Reports  (6/23/21)
Aclaris Therapeutics' new clinical trial data and a recent financing are discussed in an H.C. Wainwright & Co. report. More >

Biotech Reports Encouraging Efficacy Data in Wet AMD, Target Price Raised 66%
Source: Streetwise Reports  (6/23/21)
These new results, from a Clearside Biomedical trial, are presented and interpreted in a ROTH Capital Partners report. More >

3D Systems and CollPlant Biotech to Create Bioprinted Breast Reconstruction Treatment Solutions
Source: Streetwise Reports  (6/22/21)
3D Systems Corp. shares rose 27% after the company reported it is partnering with CollPlant Biotechnologies to develop bioprinted solutions use to improve breast reconstruction treatments. More >

Anavex Posts Strong Correlated Biomarker Data in Phase 2 Adult Rett Syndrome Trial
Source: Streetwise Reports  (6/21/21)
Anavex Life Sciences shares traded 13% higher after the company reported that ANAVEX®2-73 (blarcamesine) biomarker correlated highly with the predetermined efficacy endpoints in its Phase 2 clinical trial of adult patients with Rett syndrome. More >

Entera Bio Granted Patent for Oral Parathyroid Hormone by EU Patent Authority
Source: Streetwise Reports  (6/17/21)
Entera Bio shares traded 25% higher after the firm received a foundational patent from the EU patent office for its oral parathyroid hormone using its platform oral protein delivery technology to treat osteoporosis and hypoparathyroidism. More >

Biotech Reports Positive Preclinical COVID-19 Study Results
Source: Streetwise Reports  (6/16/21)
These data and next steps for Novan's antiviral SB019 are provided in a ROTH Capital Partners report. More >

Immuno-oncology Firm Advances Lead Asset in Mesothelioma
Source: Streetwise Reports  (6/16/21)
The status of ONCOS-102 in several of Targovax's development programs is discussed in an H.C. Wainwright & Co. report. More >

Altimmune Posts Positive Interim Weight Loss Results in Phase 1 ALT-801 Trial
Source: Streetwise Reports  (6/16/21)
Altimmune Inc. shares traded 16% higher after the company reported positive interim data from a Phase 1 study of ALT-801 in overweight and obese trial participants. More >

Clearside Biomed Shares Rise 37% on Positive Data in Phase 1/2a Wet AMD Trial
Source: Streetwise Reports  (6/15/21)
Clearside Biomedical shares reached a new 52-week high after the company reported that the first cohort in its dose-escalating Oasis Trial of CLS-AX for treatment of neovascular age-related macular degeneration met all primary endpoints. More >

Enochian Bio's Shares Rise 54% After FDA Accepts Pre-IND Request for Potential HIV Cure
Source: Streetwise Reports  (6/14/21)
Shares of Enochian Biosciences Inc. traded higher after the company reported that the U.S. Food and Drug Administration accepted a pre-investigational new drug request for a potential functional cure or treatment for human immunodeficiency virus. More >

Sorrento's COVID Test Approved in Mexico
Source: Streetwise Reports  (6/9/21)
This and other recent developments involving Sorrento Therapeutics' pipeline and partners are covered in a Dawson James Securities report. More >

Tilray Shares Climb Higher on Roll Out of New Medical Cannabis Brand Symbios
Source: Streetwise Reports  (6/9/21)
Tilray Inc. shares traded 11% higher after the company reported the launch of a new medical cannabis brand, Symbios, designed to provide medicinal users with a broader spectrum of formats and cannabinoid potencies at improved price points. More >

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom
Source: McAlinden Research for Streetwise Reports  (6/4/21)
McAlinden Research Partners notes that continued advances in psychedelic therapies show potential to drive an investment boom that could reshape the future of medicine and mental health therapies. More >

Kindred Bio Shares Rise 29% after Achieving 100% Survival Rate in Canine Parvovirus Study
Source: Streetwise Reports  (6/3/21)
Kindred Biosciences Inc. shares reached a new 52-week high after the company reported its parvovirus monoclonal antibody, KIND-030, demonstrated highly positive results in preventing deaths in dogs infected by parvovirus. More >

Drug Repurposing Firm Launches Clinical Research Program in Pancreatic Cancer
Source: Streetwise Reports  (6/3/21)
Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors. More >

Innovative Life Sciences Company Boosts Immune Function in Livestock Without the Use of Antibiotics
Source: Streetwise Reports  (6/2/21)
Avivagen's OxC-betaâ„¢ Livestock products could play a pivotal role in the global mandate to remove all in-feed antibiotics as growth promoters. More >

Biotech Receives National Cancer Institute Resources Award for Ovarian Cancer Vaccine Program
Source: Streetwise Reports  (6/2/21)
The award and other recent developments at Anixa Biosciences are covered in an H.C. Wainwright & Co. report. More >

Constellation Pharma Shares Sparkle on $1.7 Billion Buyout Offer
Source: Streetwise Reports  (6/2/21)
Shares of Constellation Pharmaceuticals Inc. traded 65% higher after the company reported it entered into an agreement to be acquired by MorphoSys AG in an all-cash transaction for $34 per share. More >

Analyst: Clinical News, Catalysts Portend 'Rich' Q2/21 for Biopharma
Source: Streetwise Reports  (5/26/21)
Second-quarter clinical events related to Anavex Life Sciences' pipeline are summarized in a Dawson James Securities report. More >

Analyst: New Data Show Cancer Therapeutic 'Continues to Deliver Benefit'
Source: Streetwise Reports  (5/26/21)
Data from two of Oncternal Therapeutics' clinical trials in oncological indications are discussed in an H.C. Wainwright & Co. report. More >

Verastem Shares Rise 25% as FDA Issues Breakthrough Therapy Designation for Ovarian Cancer Drug
Source: Streetwise Reports  (5/24/21)
Verastem Inc. shares reached a new 52-week high after the company reported its VS-6766 in combination with defactinib was granted breakthrough therapy designation by the FDA for treatment of recurrent low-grade serous ovarian cancer. More >

Biopharma Has 'Trials Progressing; Multiple 2022 Data Readouts' Including for PTSD
Source: Streetwise Reports  (5/19/21)
Updates on Aptinyx's three central nervous system drug candidates and the company's Q1/21 earnings are delivered in an H.C. Wainwright & Co. report. More >

Analyst Highlights Two Key Catalysts for Biotech
Source: Streetwise Reports  (5/19/21)
The biopharma aTyr's upcoming drug application and clinical-trial results are discussed in a ROTH Capital Partners report. More >

Sarepta Therapeutics Posts Positive Results in Duchenne Muscular Dystrophy Study
Source: Streetwise Reports  (5/18/21)
Sarepta Therapeutics shares traded 8% higher after the company reported its investigational gene therapy SRP-9001, used for treating Duchenne's Muscular Dystrophy, had "positive 12-week expression and safety results." More >